# Pixyl

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pixyl

- Industry: Medical Devices & Equipment
- Headquarters: La Tronche, France
- Website: www.pixyl.ai/
- Total disclosed funding: $2.1M
- Latest round: Series B (Feb 11, 2021)
- Investors on record: 5

## About

Pixyl SAS, based in France, specializes in advanced AI-driven medical technology to improve the analysis of brain MRI images, focusing on neuroinflammatory and neurodegenerative disorders.Founded in 2015 in La Tronche, France, Pixyl SAS develops innovative solutions for medical imaging analysis. The company has not undergone any pivots or changes in its operational strategy. It was co-founded by Michel Dojat and Senan Doyle, with Senan Doyle currently serving as CEO. Pixyl SAS has secured a total of EUR 1.00 mn through its funding efforts, culminating in its latest funding round, Series C, which raised EUR 1.00 mn. The company has a current valuation of EUR 7.43 mn and has completed 7 deals, with the most recent deal dated March 10, 2025.Pixyl SAS primarily offers Pixyl.Neuro, an AI-powered medical technology designed to enhance the analysis of brain MRI images for neuroinflammatory and neurodegenerative disorders. Utilizing proprietary algorithms, the software detects anomalies in MR images, providing essential diagnostic support for healthcare providers. It has received FDA 510(k) clearance and certification as a CE-marked class IIa medical device by TUV-Rheinland. The primary users of Pixyl.Neuro are medical professionals, notably radiologists and neurologists, who benefit from rapid analyses that can be completed in under five minutes, aiding in the formulation of effective treatment plans. The company targets markets throughout Europe and North America, as well as other regions where advanced diagnostic tools are required.In the fiscal year 2022, Pixyl SAS reported revenues of EUR 146,447.1. The company operates on a B2B model, providing its flagship product, Pixyl.Neuro, directly to hospitals and healthcare institutions. Clients typically enter partnership agreements for software access, which may involve subscription-based pricing or one-time licensing fees, allowing for seamless integration into existing radiology workflows. Revenue is generated as healthcare providers adopt the software to enhance their diagnostic capabilities, reflecting a commitment to innovation and collaboration with medical experts.In March 2025, Gleamer Sas, a portfolio company of multiple investors, including Elaia Partners, acquired Pixyl SAS, aiming to bolster its position in the radiology AI industry. This acquisition is intended to establish Gleamer Sas as a unique provider with a comprehensive suite of imaging solutions across various modalities, including CT, MRI, X-ray, and mammography. The rationale for this acquisition emphasizes the goal of enhancing market leadership. Future growth strategies involve the development of new products and expansion into new markets, seeking to leverage the integration of Pixyl’s technology within Gleamer’s offerings.

## Funding rounds

- Series B, Feb 11, 2021, $1.5M — Elaia Partners, Bpifrance, IT-Translation, Casra Capital, Holnest
- Series A, Feb 13, 2017, $0.6M — IT-Translation, Casra Capital

## Investors

- IT-Translation (https://capitalatlas.ai/funds/it-translation) — Series A, Series B
- Casra Capital — Series A, Series B
- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Series B
- Bpifrance — Series B
- Holnest — Series B